Ruboxistaurin: PKC-beta inhibition for complications of diabetes. - Wikidata - wikimedia - TriplyDB

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

http://www.wikidata.org/entity/Q37636163

about

The Novel PKCθ from Benchtop to Clinic Mechanisms of drug resistance in kinases.Diabetic macular edema: therapeutic options.Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.Protein kinase Cβ2 inhibition reduces hyperglycemia-induced neural tube defects through suppression of a caspase 8-triggered apoptotic pathway.Novel drugs and their targets in the potential treatment of diabetic retinopathy.Protein kinase C isozymes as regulators of sensitivity to and self-administration of drugs of abuse-studies with genetically modified mice.RhoA/rock signaling mediates peroxynitrite-induced functional impairment of Rat coronary vessels Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2.Protein kinase C controls vesicular transport and secretion of apolipoprotein E from primary human macrophages.Hyperglycemia-induced protein kinase C β2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling.PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice.Emerging drugs for diabetic neuropathy.Oxidative stress in early diabetic nephropathy: fueling the fire.Diabetic neuropathy: cellular mechanisms as therapeutic targets.Diabetic macular edema: current and emerging therapies.Systems kinomics for characterizing host responses to high-consequence pathogens at the NIH/NIAID Integrated Research Facility-Frederick.Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease Reactive oxygen species: sources, consequences and targeted therapy in type 2 diabetes.PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).Glycine Protects H9C2 Cardiomyocytes from High Glucose- and Hypoxia/Reoxygenation-Induced Injury via Inhibiting PKCβ2 Activation and Improving Mitochondrial Quality.Structural basis of conformational variance in phosphorylated and non-phosphorylated states of PKCβII.Protein Kinase C (PKC) Isozymes and Cancer

P2860

Q27024068-AB633F22-35B4-49A8-89A4-944516F6C816 Q27692567-9E31E4EE-3ABF-4FDD-9462-145DDB505F32 Q34185374-67AECD71-2788-40CC-83DC-3F64AA230744 Q34553087-4CE1A0F9-4C8A-4E59-BF1A-98A128391226 Q34673067-74AA7435-1E72-438C-9F7C-5E17F41290CD Q34688209-E25B84C9-7629-41A2-B896-51C86D93A214 Q34761380-41680F37-64FE-4716-8B94-7C1316FDD57F Q36159672-0D43104F-2CFF-4EBF-A9E4-C5462584103D Q36312528-E9A0DA93-C67A-481D-A03D-B285C96EB4EB Q36620898-430E0E32-E399-488D-9725-F34F98CA1EA4 Q37015027-F628B061-F975-405D-B667-9DE9BC852821 Q37397476-33048123-BFE9-4C29-9683-BE65345307A7 Q37783301-867752BB-7A4A-46E9-A848-E2F4BE12C7F1 Q37820092-8CE5185D-F5A0-4461-88A0-E180CE4DBFC3 Q37930962-BF6E608D-900C-4C34-8794-03084F2BBB34 Q37985854-3AFC1ACD-A405-4F7F-9D05-49079CCE91F5 Q38192567-FE09F64D-F5EA-44D1-998D-A90F2FF01FCD Q38798588-5A3FF51E-35C2-4AA6-8BAB-14666DCCAEBD Q38834586-12C73C20-3340-400B-AFC9-5E186AD4B6E1 Q38880678-37B78D5F-8BB9-46BA-9F54-6B97DCCEB48B Q42125422-5E3FB13C-6512-4A16-BA0E-1E6584B67936 Q54232641-8ACD2E26-2AF2-4024-845A-1C3DB14A2298 Q55018528-094ABC6B-A3E9-4FA5-BE9D-FB9C63E9CB0B Q55072903-AB2C1D66-B005-46FF-8614-72ABD18F5E26 Q59072618-D93929D8-D9D5-4893-9D59-6D92F2121C12

P2860

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

http://www.wikidata.org/entity/Q37636163

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

@en

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

@nl

type

label

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

@en

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

@nl

prefLabel

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

@en

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

@nl

P1433

Q37636163-F73E9BA3-4616-458F-BCDB-AD3504D48A72

P1476

Q37636163-5C84DE38-1259-4710-9538-F863F9A06C14

P2093

Q37636163-33351D15-08C0-4CE1-9936-45979F45C846

Q37636163-977A8907-C4F2-4379-A762-C6F611521673

P2860

Q37636163-027C3F5E-4B90-4FA0-81B4-D74015887E84

Q37636163-03DC0115-C185-4927-9C5D-F17D29228FB3

Q37636163-040ADD10-8AA0-4302-87F4-22D95DA412B2

Q37636163-06231F26-D6DC-4F6F-894E-F6A746630850

Q37636163-14517F0A-F405-4375-B549-9EE4A141B0C1

Q37636163-18BDE461-17A7-4548-AE3C-397AA49181B9

Q37636163-1E2F015B-ABEF-4E4A-86D8-89CECB1CA69A

Q37636163-1F434E71-6808-49E4-AE95-989E565FE4C8

Q37636163-23FFEC42-3D78-4D1E-9892-2791A170E2F3

Q37636163-24124385-6983-4B8A-B406-26350551EA26

P304

Q37636163-2E95E119-830A-4809-8CDE-5AE5E393E8C4

P31

Q37636163-005C141C-BF6E-449F-A94C-3B313F84D80F

P356

Q37636163-4D7D19BB-F4CB-4555-8CD1-97DE6539CE8A

P407

Q37636163-24BC7C71-8501-453D-8884-65A7C3576E8D

P433

Q37636163-135B64E4-9CAE-42A8-9BDF-91F25241A50F

P478

Q37636163-2988A44A-CF15-4E1B-9770-675232077F31

P577

Q37636163-25513A4B-562A-4ED1-BA5F-B53E4159C05E

P698

Q37636163-DAB4980E-DF4A-4EE2-907B-7ACFA17A3565

P356

14656560903401620

P1433

Expert Opinion on Pharmacotherapy

P1476

Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

@en

P2093

Matthew J Sheetz

http://www.w3.org/2001/XMLSchema#string

Ronald P Danis

http://www.w3.org/2001/XMLSchema#string

P2860

The extended protein kinase C superfamily

Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Prevalence of patients with type 2 diabetes mellitus reaching the American Diabetes Association's target guidelines in a university primary care setting

Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition

Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes

Protein kinase C is regulated in vivo by three functionally distinct phosphorylations

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

P304

2913-2925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656560903401620

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19929710

http://www.w3.org/2001/XMLSchema#string